Dynavax is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel vaccines aimed at combatting infectious diseases. Their proprietary CpG 1018 adjuvant underpins a diverse vaccine portfolio, including HEPLISAV-B®, approved in the U.S. and EU for adult hepatitis B prevention. Dynavax collaborates with global partners to advance vaccines for a variety of conditions, including COVID-19 and shingles. Headquartered in the San Francisco Bay Area with a manufacturing facility in Düsseldorf, Germany, Dynavax fosters a workplace culture where employees are valued and engaged, emphasizing integrity, quality, and safety in all operations. They support a flexible work environment that encourages remote work and in-person collaboration as needed. This commitment to public health and employee development contributes to Dynavax's ongoing mission to enhance vaccination efforts worldwide.